Innovation
JX-594
- JX-594 - Programmed to Destroy Cancer.
- Four clinical trials completed and three ongoing
- Over 120 patients treated to date
-
Significant publication in the prestigious journal, Nature, showing the ability of
JX-594 to be delivered intravenously. 
News
- Jennerex Announces First Patient Treated in Phase 2a Clinical Trial of JX-594 as a Neoadjuvant Therapy in Colorectal Cancer Patients Undergoing Surgery
- Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients with Advanced Liver Cancer
- Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer